A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Clinical trial NCT05646862 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05646862
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-07
- Primary completion
- 2026-11-13
- Enrollment
- 420
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.